Anavex Life Sciences Corp (AVXL)

[Joseph_K]

Shouldn't there be reports of big insider purchases by now?

I think there's broad agreement now on this board both that (a) Missling has definitively said that the P2b/3 trial endpoints were met and that (b) some of the expected critical data or analysis supporting that statement is missing. (Even the most bullish here, even if they believe the Odds Ratio is a totally acceptable alternative to comparison of means differences, have to agree that the n – the number of patients over the thresholds in the Odds Ratio calculations – matters materially and is missing.) IMO, a consequence of a+b is a vast mismatch between the company's claimed prospects and its share price.

If you were an insider and knew for a fact that the endpoints were met, wouldn't you load up on the stock at $8/share? Why aren't we seeing this?